Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

HhAntag691 4tazarotene 2sonidegib 2Photochemotherapy 2Aminolevulinic Acid 21-phenyl-3,3-dimethyltriazene 2Watchful Waiting 1Solutions 1Sirolimus 1Red Light 1Nivolumab 1NVP-BKM120 1Microarray Analysis 1Mass Spectrometry 1Ipilimumab 1Gene Expression Profiling 1Comparative Genomic Hybridization 1Carnitine 1Blue Light 1Biopsy 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Basal Cell Nevus Syndrome × Nivolumab × Clear all
NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Columbia University

Phase 2 Withdrawn
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡